ABSTRACT

Introduction  Management of traumatic brain injury (TBI) includes invasive monitoring to prevent secondary brain injuries. Intracranial pressure (ICP) monitor is the main measurement used to that intent but cerebral hypoxia can occur despite normal ICP. This study will assess whether the addition of a brain tissue oxygenation (PbtO2) monitor prevents more secondary injuries that will translate into improved functional outcome.

Methods and analysis  Multicentre, randomised, blinded-endpoint comparative effectiveness study enrolling 1094 patients with severe TBI monitored with both ICP and PbtO2. Patients will be randomised to medical management guided by ICP alone (treatment team blinded to PbtO2 values) or both ICP and PbtO2. Management is protocolised according to international guidelines in a tiered approach fashion to maintain ICP <22 mm Hg and PbtO2 >20 mm Hg. ICP and PbtO2 will be continuously recorded for a minimum of 5 days. The primary outcome measure is the Glasgow Outcome Scale-Extended performed at 180 (+30) days by a blinded central examiner. Favourable outcome is defined according to a sliding dichotomy where the definition of favourable outcome varies according to baseline severity. Severity will be defined according to the probability of poor outcome predicted by the IMPACT core model. A large battery of secondary outcomes including granular neuropsychological and quality of life measures will be performed.

Ethics and dissemination  This has been approved by Advarra Ethics Committee (Pro00030585). Results will be presented at scientific meetings and published in peer-reviewed publications.

Trial registration number  ClinicalTrials.gov Registry (NCT03754114).

INTRODUCTION

Traumatic brain injury (TBI) is a major cause of death and disability in modern industrialised societies. The most recent estimates from the Centers for Disease Control and Prevention indicate that in the USA alone, 3.5 million individuals experience a TBI annually, of which 300 000 are hospitalised and discharged alive. Among the 300 000 hospitalised survivors, over 40% experience long-term disability.

Historically, monitoring of patients with severe TBI focused on intracranial pressure (ICP) and cerebral perfusion pressure (CPP) to prevent secondary injury. Although limiting elevation of ICP is an important part of TBI management, the only randomised...
controlled trial comparing an ICP-driven management versus clinical management based on imaging and physical examination did not show improvement in outcome with invasive monitoring.\textsuperscript{7} The management of elevated ICP (eICP) is complex and heterogeneous, this likely reflects the difficulty of applying a one-size-fits-all protocol to a heterogeneous population of patients who require individualised care.\textsuperscript{8,9,13} The physiological rationale underlying ICP management is to preserve oxygen delivery to the brain, using CPP as a surrogate for cerebral blood flow (CBF). There are numerous reasons why brain oxygen delivery can be affected despite ICP or CPP being normal.\textsuperscript{10-12} In fact, oxygen diffusion in the brain parenchyma is the rate limiting step of delivery\textsuperscript{13} and is affected by the presence of oedema or microcirculatory failure.\textsuperscript{14} Devices that measure brain tissue oxygen (PbtO\textsubscript{2}) are now readily available at bedside. Numerous studies have shown that cerebral hypoxia is common, reversible, may be able to measure cerebral ischaemic burden and independently associated with functional outcome.\textsuperscript{11,13-18} The use of PbtO\textsubscript{2} was recently the subject of a consensus statement guideline, highlighting the fact that multimodal monitoring allows for management refinement compared with ICP management alone.\textsuperscript{19}

TBI management heterogeneity requires that any multicentre clinical trial protocol allows various treatment options based on bedside evaluation of cerebral physiology while maintaining the rigour and clinical standardisation necessary to conduct a randomised clinical trial (RCT). BOOST-2, a multicentre RCT, found that treatment of elevated ICP and correction of low PbtO\textsubscript{2} decreased the total cumulative ischaemic burden compared with treatment of elevated ICP alone (p=0.0000002).\textsuperscript{20} Furthermore, a trend in improved functional outcome at 6 months was supportive of the predetermined non-futility hypothesis.

The primary objective of BOOST-3 is to determine whether a treatment protocol, informed by PbtO\textsubscript{2} plus ICP monitoring, results in improved neurological outcome measured by the Glasgow Outcome Scale-Extended (GOS-E) 6 months after injury compared with treatment guided by ICP monitoring alone.

**METHODS**

**Trial design, study setting and study population**

BOOST-3 is a two-arm, single-blind, randomised, controlled, phase III, multicentre trial to determine whether treatment algorithms informed by PbtO\textsubscript{2} and ICP monitoring improve subject outcomes more than treatment informed by ICP alone. The complete study protocol, manual of operating procedures (MOP) and other documentation can be found on the study website: siren.network/clinical-trials/boost-3. Inclusion and exclusion criteria are summarised in figure 1.

BOOST-3 includes 47 level 1 trauma centres that are experienced with active clinical use of PbtO\textsubscript{2}-guided patient management across the USA and Canada. These sites place PbtO\textsubscript{2} and ICP monitors according to Brain Trauma Foundation (BTF) guidelines as part of their standard of care for patients with severe TBI. Monitors will thus be inserted following local standard practice patterns. Of these patients, those who meet eligibility criteria for the study will be randomised. Specifically as per inclusion criteria, randomisation will occur if the decision to place catheters is made within 6 hours from arrival to the enrolling centre and no later than 12 hours from injury (figure 1).

Both ICP (Codman, Camino or EVD) and PbtO\textsubscript{2} monitors (Integra Licox or Raumedic Neurovent) will be used as per local standard practice. Correct catheter placement will be confirmed by a head CT scan within 24 hours of placement. PbtO\textsubscript{2} probe reliability will be assessed performing a fractional inspired oxygen (FiO\textsubscript{2}) challenge (blinded in the ICP-only group) with an appropriate response defined by an increase of at least 5 mm Hg. In the PbtO\textsubscript{2}+ICP group, non-functioning PbtO\textsubscript{2} probes will be replaced.

The trial is being conducted in the SIREN (Strategies to Innovate EmeRgENcy Care Clinical Trials Network) network, which is an emergency care clinical trials network funded by the National Institute for Neurological Disorders and Stroke (NINDS), the National Heart, Lung and Blood Institute and the National Center for Advancing Translational Science to improve outcomes of subjects with acute illness and injury.

**Randomisation and blinding**

Subjects are randomised in a 1:1 ratio to a treatment protocol informed by both ICP and PbtO\textsubscript{2} or by ICP alone, using a covariate-adjusted randomisation scheme (figure 1). The randomisation scheme controls imbalances in the overall treatment distribution, within injury severity category, and within clinical site.

Both arms will have a PbtO\textsubscript{2} probe inserted, but the clinical teams will be blinded to PbtO\textsubscript{2} values in the ICP-only group. Daily FiO\textsubscript{2} challenges will be conducted by unblinded study personnel not involved in patient care to assess probe reliability.

The primary outcome assessment will be centrally performed by trained personnel blinded to group assignment (see the Outcome section).

**Intervention**

A Clinical Standardization Committee (CST) for the BOOST-3 trial developed general targets for physiological variables for both groups (table 1) and finalised the MOP. Arterial blood pressure monitoring for CPP purposes will be standardised to the level of the heart.

The patient’s clinical course will fall into four different clinical scenarios based on monitoring information, three of which (types B, C and D, defined in figure 2) will require management strategies. Type D combines the treatment options of type B and C scenarios.
Scenarios for type B (box 1) and type C (box 2) are addressed with a set of physiologically based interventions to correct ICP and PbtO₂. The treatment protocol is tiered in a hierarchical fashion, with less aggressive interventions attempted before more aggressive manoeuvres. Interventions in this protocol were adapted from the BTF 2016 Guidelines for the Management of Severe Traumatic Brain Injury and the American College of Surgeons–Trauma Quality Improvement Program 2015 guidelines. Some interventions represent expert opinions. Treatment algorithms were developed...
through discussions between BOOST investigators with expertise in critical care medicine and neurosurgery (CST). The protocol represents an attempt to minimise centre-to-centre variability and to facilitate interpretation of the PbtO₂ information using local expertise.

An episode that requires intervention is triggered by abnormalities in ICP or PbtO₂ lasting more than 5 min. Treatments must be initiated within 15 min of the start of an episode. Patients may start in one type of scenario and then move to another scenario while they are receiving treatments. The initial choice of a treatment option from any tier for any particular scenario should be determined based on what is felt to be the most effective intervention for the current clinical situation, participant characteristics and local protocols. Any intervention chosen should be aimed at addressing the underlying pathophysiology that is contributing to the episode. At least one treatment in tier 1 must be tried before moving on to tier 2. Tier 3 treatments are optional. While there is no maximum number of treatment options that can be attempted from any one tier, no more than 60 min should be spent trying tier 1 interventions prior to moving on to tier 2. The bedside treatment team has the option to progress to higher tiers as rapidly as they feel is clinically indicated.

Some interventions in boxes 1 and 2 are noteworthy.

**Box 1 Scenario B: treatment options for isolated ICP increase >22 mm Hg**

**TIER 1**: must begin within 15 min of abnormality. No particular order.
- Adjust head of bed to lower ICP.
- Ensure temperature <38°C.
- Titrate pharmacological analgesia or sedation to effect.
- CSF drainage (if EVD available).
- Optimise CPP to max 70 mm Hg with fluid boluses or vasopressors as clinically appropriate. May assess cerebral autoregulation as per local protocol to manage CPP targets.
- Optimal CPP in tier 1 is >70 mm Hg. If CPP <70 mm Hg, use higher doses of HTS or give vasopressors. If CPP >70 mm Hg for >5 min, consider reduction of CPP.
- Adjust ventilator for a target PaO₂ of 35–40 mm Hg (target pH of 7.35–7.45).
- Low-dose mannitol (0.25–0.5 g/kg).
- Low-dose HTS (include 1.5%–3%). This tier does not include higher concentrations of HTS. Titrate to effect (CPP control) and maintain Na <160 mEq/L.
- Initiate or titrate anti-epileptic medications.

**TIER 2**: initiate within 60 min if tier 1 therapies are ineffective. No particular order.
- Repeat head CT; treat surgically remediable lesions according to guidelines.
- Adjust temperature to 35°C–36°C, using active cooling measures.
- NMB, use a bolus dose to determine effect. If effective, perfusion may be used. NMB should be rapidly weaned upon clinical stabilisation.
- Optimise CPP: may increase CPP above 70 mm Hg with fluid boluses or vasopressors.*
- Adjust ventilatory rate to target PaO₂ of 33–38 mm Hg (target pH of 7.35–7.45).
- High-dose mannitol (1–1.5 g/kg) or higher frequency of low-dose mannitol (0.25–0.5 g/kg) if osmolality <320.
- High-dose HTS bolus (7.5%, 30 mL of 23.4%). May repeat if Na levels are <160 mEq/L.

**TIER 3** (tier 3 therapies are optional). No particular order.
- Adjust ventilatory rate for target PaO₂ of 30–35 mm Hg (target pH of less than 7.5).
- Pentobarbital coma, according to local protocol. An initial bolus dose of 5 mg/kg should be used to determine effectiveness. If effective, a continuous infusion may be used. Pentobarbital should be rapidly weaned upon clinical stabilisation.
- Decompressive craniectomy.
- Adjust temperature to 32°C–35°C, using active cooling measures.
- Other salvage therapy per local protocol and practice patterns.

*There is a potential for harm related to augmentation of CPP above 70 mm Hg with vasopressors.

CPP, cerebral perfusion pressure; PaCO₂, arterial carbon dioxide pressure; PaO₂, arterial oxygen pressure; PT, Prothrombin time; PTT, Partial Thromboplastine time.
Box 2 Scenario C: treatment options for isolated PbtO₂ <20 mm Hg

TIER 1: must begin within 15 min of abnormality. No particular order.
► Adjust head of the bed.
► Ensure temperature <38°C.
► Optimise haemodynamics to ensure adequate CBF and avoid diffusion gradient:
  ▪ Resuscitation: address hypovolaemia.
  ▪ Diuresis: avoid hypervolaemia, consider furosemide or other agent for diuresis.
► Optimise CPP up to 70 mm Hg maximum with fluid boluses or vasopressors as clinically appropriate. May assess cerebral autoregulation as per local protocol to manage CPP targets.
► PaO₂ adjustment (obtain ABG first†):
  ▪ Pulmonary toilet with suctioning of secretions (bronchoscopy is not included in this tier as an option).
  ▪ Increase FiO₂, to a maximum of 60%.
  ▪ Adjust PEEP by a maximum of 5 cm H₂O over baseline.
► Adjust minute ventilation to achieve a PaCO₂ of 38–42 mm Hg (target pH of 7.35–7.45). Further lowering of PaCO₂ should not be done if pH >7.45. PaCO₂ should not be increased if pH is <7.35.
► Initiate or titrate anti-epileptic medications.
TIER 2: initiate within 60 min if tier 1 therapies are ineffective. No particular order.
► Increased sedation.
► Decrease ICP to <15 mm Hg.
► CSF drainage.
► NMB, use a bolus dose to determine effect. If effective, perfusion may be used. NMB should be rapidly weaned upon clinical stabilisation.
► Optimise CPP: may increase CPP above 70 mm Hg with fluid boluses or vasopressors.
► PaO₂ adjustment (obtain ABG first†):
  ▪ Perform bronchoscopy.
  ▪ Increase FiO₂, a maximum of 100%†. Wean rapidly when clinically stable (decrease FiO₂ by 5% every 30 min).
  ▪ Adjust PEEP in increments of 3–5 cm H₂O.
► Adjust minute ventilation to increase PaCO₂ to 40–45 mm Hg (target pH of 7.35–7.45).
► Transfusion of red blood cells.
TIER 3 (tier 3 therapies are optional). No particular order.
► Adjust minute ventilation to increase PaCO₂ >45 mm Hg (target pH of 7.30–7.45).
► Increase cardiac output with inotropes (milrinone, dobutamine).
► Assess for vasospasm with transcranial dopplers, CT angiogram or cerebral angiogram.
► Hyperventilation to address possible reverse Robin Hood syndrome.
► Other potential causes/interventions for low PbtO₂ should be considered:
  ▪ Consider cortical spreading depolarisation via ECog.
  ▪ Assess for pulmonary embolism.
  ▪ Assess for cerebrovascular venous thrombosis.
► Other salvage therapy based on local protocol and practice patterns.

*Obtain ABG to confirm that oxygenation is in desired range before treating with PaO₂ adjustments. Note that increasing PaO₂ above 150 mm Hg might imply over-treatment by PaO₂, and prevents detection of another potential cause of low PbtO₂.
†This option should only be used when PbtO₂ is persistently less than 20 mm Hg and other variables contributing to low PbtO₂ have been addressed and controlled. There is a potential for harm related to augmentation of CPP above 70 mm Hg with vasopressors.

Box 2 Continued

Optimising CPP

Target range for CPP is unknown and may depend on the patient’s autoregulatory status. 4 As such, optimisation of CPP might be informed by cerebral autoregulation testing. 21 We advise there is a potential for harm related to augmentation of CPP above 70 mm Hg, 22 but some patients may require it. We also recognised that lowering CPP below 60 mm Hg might be an option to treat eICP when cerebral autoregulation is absent (Lund therapy). 23 Finally, CPP optimisation also includes improvement in CBF though improvement in cardiac output (inotropy).

Increasing arterial oxygen pressure

Obtaining an arterial blood gas before treating with arterial oxygen pressure (PaO₂) adjustments is mandatory. Increasing PaO₂ above 150 mm Hg might imply overtreatment by PaO₂ and prevents detection of another potential cause of low PbtO₂. Calculating the brain oxygen ratio (BOx ratio = PbtO₂/PaO₂) might help recognise this situation. 10 Increasing PaO₂ above 150 mm Hg should only be used if PbtO₂ is persistently less than 20 mm Hg and other variables contributing to low PbtO₂ have been addressed and controlled first.

Reverse Robin Hood syndrome

PbtO₂ probe located in an area already maximally vasodilated might measure a drop of flow (low PbtO₂) if other areas of the brain vasodilate (potentially because of hypoventilation), creating a ‘steal’ by diverting flow from the area measured. Treatment requires vasoconstricting the normal brain to redirect the flow towards the area measured using hyperventilation. 24–26

Withdrawal of life-sustaining treatments (WLST) during the first 5 days will only be considered in dire circumstances or if requested by the patient’s family. If the study subject undergoes WLST during the first 5 days of treatment, the site principal investigator (PI) will be required to notify the study leadership team. Reasons for WLST will be carefully documented.

Outcomes

The primary outcome measure is the GOS-E performed at 180 (±30) days by a blinded central examiner. All injury-related disabilities are assessed for the primary measure.

A complete battery of secondary measures will be assessed, including: survival at hospital discharge, total brain hypoxia burden, Functional Status Examination, Rey Auditory Verbal Learning Test, Trail Making Test...
Part A and B, Wechsler Adult Intelligence Scale (WAIS-IV), Processing Speed Index, Rivermead Post-Concussion Symptoms Questionnaire, Brief Symptom Inventory 18 and Satisfaction with Life Scale.

Data collection, data monitoring and adverse events

The study data will be managed using the WebDCU system. This web-based clinical trial management system will be used for regulatory document management, subject randomisation, data entry, data validation, project progress monitoring, subject tracking, user customisable report generation and secure data transfer. Reports will be generated to monitor study progress and patient recruitment at each site. These reports will provide centre-specific information on the number of subjects with missing or incomplete data and number of data queries.

Information specific to PbtO₂, ICP and CPP monitoring will be collected for up to 5 days. Continuous digital recordings of these values will be captured on a bedside dedicated integrated platform (CNS Monitor, Moberg ICU Solutions, Amber, Pennsylvania, USA). This will allow precise calculation of ischaemic burden (time spent with PbtO₂ below 20 mm Hg) and eICP burden (time spent above 22 mm Hg). A custom built-in clinical decision algorithm based on the tier treatments (CNS Carepath, Moberg ICU Solutions, Amber, Pennsylvania, USA) can be used to help guide bedside clinicians to select the appropriate intervention for a given type of scenario. Local study personnel can review Carepath and the medical record to identify alarms and actions taken to correct them on the electronic case report form for the first 5 days.

The clinical site PI, independent medical safety monitor (IMSM), and data and safety monitoring board (DSMB) appointed by the NINDS are responsible for the timely review of the safety data. The DSMB will operate in accordance with NINDS guidelines. The DSMB will evaluate open and closed reports prepared by the Data Coordinating Center on a semiannual basis.

General data quality will be monitored by the Clinical Coordinating Center and will include a combination of on-site monitoring, remote monitoring and central monitoring (using web-based data validation rules, data manager review of entered data, statistical analysis and ongoing review of site metrics).

Adverse events (AEs) are defined as any untoward event or complication not previously identified, or that occurs with greater frequency or severity than previously reported, whether or not considered related to the protocol intervention. The AEs listed in table 2 are anticipated based on the known complications of severe TBI, intracranial monitoring devices and prolonged use of supraphysiological levels of oxygen. In addition, new abnormal laboratory findings that are considered by the treating physician to be clinically significant may be included as AEs.

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Expected incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute respiratory distress syndrome (ARDS)</td>
<td>5%</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>25%</td>
</tr>
<tr>
<td>Sepsis</td>
<td>5%</td>
</tr>
<tr>
<td>Septic shock</td>
<td>3%</td>
</tr>
<tr>
<td>Haematoma requiring craniotomy for evacuation</td>
<td>0.5%</td>
</tr>
<tr>
<td>Central nervous system infection</td>
<td>&lt;0.5%</td>
</tr>
</tbody>
</table>

Serious AEs are any AE that results in any of the following outcomes or actions: (1) death due to any cause; (2) a life-threatening adverse experience; (3) inpatient prolongation of existing hospitalisation; (4) a persistent or significant disability/incapacity; (5) an important medical event that may require medical or surgical intervention to prevent one of the outcomes listed above. These must be reported within 24 hours of discovery.

All AEs are collected through day 6 or discharge, whichever comes first; serious AEs will be reported through subject end of study. The IMSM will adjudicate serious AEs for seriousness, relationship to the study intervention and expectedness.

Statistical considerations

Favourable outcome is defined according to a sliding dichotomy (figure 3), where the definition of favourable outcome varies according to baseline severity. Severity will be defined according to the probability of poor outcome predicted by the IMPACT core model.28 The favourable outcome definition is more stringent for subjects with a low probability of poor outcome.

A clinically relevant effect size of 10% absolute difference in favourable outcome proportions is prespecified. In order to achieve 85% power with a two-sided type I error probability of 0.05, 880 subjects are required. This calculation assumes a 50% favourable outcome proportion in the control arm. Inflation to account for interim analysis and 7% non-adherence results in a maximum sample size of 1094 subjects.

All subjects enrolled in the study are to be followed until the end of study or until consent is withdrawn or declined and will be included in the primary intention-to-treat analysis.

Study timescale

Recruitment began Summer of 2019. The COVID-19 pandemic significantly affected early recruitment. The trial is currently recruiting patients at the rate of 15–16 patients per month. Once all sites are fully operational and recruiting, we expect recruitment to end by 2026. Allowing for the 6-month follow-up assessment, data cleaning and closure of the database, data analyses, manuscript writing and publication should take place in 2026.
Patient and public involvement

Community consultation and public disclosure are completed regionally for all enrolling sites in the USA, prior to the initiation of the clinical trial under CFR 50.24. No patient or public representative was involved in the written design of the trial.

ETHICS AND DISSEMINATION

Because all patients meeting eligibility criteria for this trial will be unresponsive and unable to provide informed consent, participants will be enrolled either with the informed consent of a legally authorised representative (LAR—see online supplemental material) or with exception from informed consent (EFIC) for emergency research (no EFIC in Canada). If no LAR is available before placement of the ICP and PbtO₂ monitors, the patient may be enrolled under EFIC. If LAR is available prior to ICP and PbtO₂ monitors being placed, consent will be sought from LAR. The complete EFIC process will be the subject of another publication since it refers to a complex ethical process.

Publication of the results of this trial will be governed by the policies and procedures developed by the Executive Committee consistent with the SIREN publication policy.

DISCUSSION

BOOST-3 is a pragmatic, physiology-based study that aims to demonstrate the superiority of combined PbtO₂+ICP-guided therapy over ICP-guided therapy alone when comparing subject outcomes at 6 months. Classic TBI management based on ICP and CPP alone has demonstrated its limitations. This management uses pressure therapy based on ICP and CPP alone has demonstrated its limitations.29 30 This management uses pressure management based on ICP and CPP alone has demonstrated its limitations.31 Analysing the physiological parameters that influence PbtO₂ values at the bedside allows for a more extensive and precise comprehension of brain pathophysiology and may result in more tailored and efficacious care to prevent secondary injuries.32

Two other trials are going to study the added value of PbtO₂ monitoring: the ongoing OXY-TC trial in France32 and the BONANZA trial in New Zealand and Australia (not yet registered on ClinicalTrials.gov). As designed, BOOST-3 will be the largest and is adequately powered to detect a clinically meaningful difference in clinical outcome that remains achievable (10% absolute difference). In comparison, the OXY-TC targets a 30% difference in outcome. Both BOOST-3 and BONANZA will be measuring PbtO₂ in a blinded fashion in the control arm allowing the evaluation of cumulative hypoxic burden between groups.

Recognising the heterogeneity of TBI characteristics and complexity of its management, BOOST-3 has standardised therapy in both groups while allowing for flexibility in treatment options. These options reflect the various possible physiological manipulations required to correct anomalies identified by the bedside physician (boxes 1 and 2). Of note, BOOST-3 protocol recognises that cerebral autoregulation status plays an important role in managing CPP threshold.33 Optimisation of CPP according to the autoregulation status might improve outcome but its management remains difficult clinically.34–36 PbtO₂ might facilitate recognition of the autoregulation status.37 38 Analysis of the continuous data capture within the BOOST-3 cohort may inform future study of the relationship between cerebral autoregulation, goal-directed therapy and patient outcome.

The BOOST-3 protocol also clearly emphasises that increasing PaO₂ in order to correct a low PbtO₂ value should be used very cautiously. Increasing PaO₂ above 150 mm Hg might imply overtreatment by PaO₂ and prevents detection of another potential cause of low PbtO₂.39 It is possible to compensate for a decrease in PbtO₂ due to low CBF by increasing PaO₂.40 Hyperoxia is known to induce cerebral vasoconstriction,40 potentially increase free radical production41 and has been associated with worse outcome in other brain ischaemic injuries.42–45 If FiO₂ is increased as a therapeutic manoeuvre, a specific FiO₂ weaning protocol is suggested. That being said, it is expected that patients with TBI managed with a PbtO₂ probe will have a higher mean PaO₂ since it is the only possible therapeutic option to address the diffusion and microcirculatory failure often seen with severe TBI.43 44 AEs related to pulmonary pathology will be closely tracked in both study groups.
The limitations of standardisation in BOOST-3 are inherent to the nature of TBI. First, there is wide variation in the phenotype of brain injury. For example, patients may have diffuse axonal injury, intraparenchymal contusion, extra-axial haematomas, subarachnoid haemorrhage or any combination of these injuries. The fact that multiparametric and PbtO₂ monitoring allow for a physiology-driven approach may globally improve the delivery of care despite the heterogeneity of disease phenotype. BOOST-3 is slated to recruit a large number of patients, which will likely help to achieve balance of injury phenotype across study groups. Furthermore, the specificity gained by measuring functional outcome through a sliding dichotomy based on initial injury should also reduce heterogeneity bias.

WLST, although strongly discouraged in the first 5 days after TBI, can still influence outcome measures. No specific protocol for prognostication and decision to withdraw care is suggested in the research protocol; treating physician acumen will determine end-of-life decisions.

An additional limitation is the relatively short time window from TBI to randomisation (less than 12 hours after injury and 6 hours after presentation at enrolling hospital), this will likely reduce generalisability of the findings to underserved communities, or those lacking access to neurosurgical expertise. This time frame was chosen to appropriately test the biological basis of PbtO₂ monitoring in the acute phase of brain injury to prevent secondary injuries. A longer interval from injury may allow for significant cerebral hypoxia before randomisation. A challenge that has been identified after start-up relates to the 6-hour time window after arrival at enrolling site, which poses a problem if the patient needs urgent surgical intervention. Allowing some flexibility in the 6-hour window allows urgent clinical needs to be addressed prior to placement of intracranial monitors. A final challenge after study start-up included the COVID-19 pandemic putting a hold on research activities thus lowering expected enrolment.

The annual cost to society resulting from TBI has been estimated to range from $83 billion to $244 billion (in 2014 dollars). Improvements in functional outcome will benefit not only affected patients but society globally. Multiple trials targeting a specific medication or pathophysiological mechanism have failed to demonstrate improvement in outcome so far. We feel that the early use of a PbtO₂-guided bundle of care will yield a different result.

Author affiliations
1 Critical Care, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada
2 Department of Medicine, Université de Montréal, Montreal, Québec, Canada
3 Department of Emergency Medicine, University of Michigan, Ann Arbor, Michigan, USA
4 Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
5 Emergency Medicine and Neurology, Neurocritical Care, University of Florida College of Medicine, Gainesville, Florida, USA
6 Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA
7 Critical Care Medicine, Neurology, & Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
8 Stanford Neurosurgery, Stanford University, Stanford, California, USA

Acknowledgements We want to acknowledge the influence that the BOOST-3 Clinical Standardization Committee had on developing the clinical application of the protocol: Lori Shutter, Lisa Merck, Ramon Diaz-Arrastia, Rocco Armonda, Francis Bernard, Randall Chesnut, Anita Fetzick, Claude Hemphill, Luke James, Ryan Kitagawa, Carol Moore, David Okonkwo, Ava Puccio, Claudia Robertson, Uzma Samadani, Danièle Sandmark, Robert Silbergleit.

Contributors RD-A wrote the protocol of this study, LAS, RD-A, SY and WB are the principal investigators of the trial and compose the steering committee. SY is responsible for the statistics and data management of the trial. WB is administering the trial. FB and LAS wrote the first draft of this manuscript. FB, LAS and LHM are part of the clinical standardisation team responsible for protocol implementation and the manual of operating procedure. FB, LAS, LHM, RD-A, SY and WB all revised and approved the final version of this manuscript.

Funding This trial is funded by the National Institute of Neurological Disorders and Stroke (NINDS) (grant number U01 NS099046).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Francis Bernard http://orcid.org/0000-0001-9121-2882
Lori A Shutter http://orcid.org/0000-0002-1390-0628

REFERENCES


